stella
beta
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) — Stella
Recruiting
Back to AML, Adult Recurrent trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(9 sites)
United States
Cedars-Sinai Medical Center, Los Angeles, California
University of California Irvine Medical Center, Orange, California
Baptist Health South Florida-Miami Cancer Institute, Miami, Florida
Norton Healthcare-Norton Cancer Institute, Louisville, Kentucky
Mass. General Hospital-Harvard, Boston, Massachusetts
Show all 9 locations
View full record on ClinicalTrials.gov